StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note released on Monday morning. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of NAVB opened at $0.04 on Monday. The company has a 50-day simple moving average of $0.04 and a 200-day simple moving average of $0.05. Navidea Biopharmaceuticals has a 52 week low of $0.02 and a 52 week high of $0.22. The firm has a market capitalization of $3.60 million, a P/E ratio of -0.60 and a beta of 1.13.
Navidea Biopharmaceuticals Company Profile
Read More
- Five stocks we like better than Navidea Biopharmaceuticals
- Why Invest in 5G? How to Invest in 5G Stocks
- AMD is Down 35%. Now is the Time to Buy the Dip
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Amazon Stands Tall: New Highs Are in Sight
- 5 discounted opportunities for dividend growth investors
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.